29 Jun 2023
In this video, Dr. Coleman Murray, Chief Operating Officer at Ferrologix, discusses how the COVID-19 pandemic has led to a growing demand for automation in the life sciences field and how these technologies are helping to solve complex problems that were not addressable before. Murray explains that the increasing accessibility of AI and automation could help to accelerate precision medicine and discusses the importance of effective scientific communication within the entire world community to tackle future threats.
This video was filmed at SLAS Europe 2023
Ferrologix
Dr. Coleman Murray is an accomplished bioengineer and entrepreneur, currently serving as the COO and Co-founder of Ferrologix Inc. With a background in lab automation and microelectromechanical systems (MEMS), he has made significant contributions to the healthcare industry. Driven by his passion for innovation, he has successfully led the development and commercialization of Ferrologix's core technology, the ratcheting cytometry platform. Having obtained his Ph.D. under the mentorship of Professor Dino Di Carlo at UCLA, Dr. Murray has a strong academic foundation in the field. His expertise in linking early-stage technologies to address specific market needs has been key in Ferrologix's growth and success. Dr. Murray's dedication to his field extends beyond his role at Ferrologix. He actively engages with the scientific community and has been involved with the Society for Laboratory Automation and Screening (SLAS) as treasurer.